HRF Inhibitors
HRF inhibitors encompass a diverse array of compounds that act either directly or indirectly to modulate HRF expression by targeting specific signaling pathways or cellular processes crucial for its regulation. These inhibitors predominantly focus on modulating the NF-κB signaling pathway, a key regulatory pathway for HRF. TPCA-1 and BAY 11-7082 inhibit HRF indirectly by suppressing NF-κB activation. TPCA-1 targets IKK, an upstream kinase of NF-κB, while BAY 11-7082 impedes IKK activity, both leading to decreased NF-κB-mediated transcriptional regulation of HRF. Parthenolide and JSH-23 target NF-κB nuclear translocation, indirectly affecting HRF expression. Parthenolide inhibits the nuclear translocation of NF-κB, a transcription factor regulating HRF, while JSH-23 prevents NF-κB from entering the nucleus. Bay 11-7085 and Celastrol inhibit NF-κB activation, thereby modulating HRF expression. Bay 11-7085 hinders the nuclear translocation of NF-κB, and Celastrol impedes the nuclear translocation of NF-κB.
IMD-0354 and Bortezomib target IKKβ and the proteasome, respectively, affecting NF-κB signaling and, consequently, HRF expression. IMD-0354 inhibits IKKβ, a kinase upstream of NF-κB, leading to decreased NF-κB-mediated transcriptional regulation of HRF. Bortezomib prevents NF-κB activation by inhibiting the degradation of IκB, an inhibitor of NF-κB. CAPE and Wedelolactone inhibit NF-κB activation, modulating HRF expression. CAPE suppresses the nuclear translocation of NF-κB, while Wedelolactone inhibits IKK, leading to decreased NF-κB-mediated transcriptional regulation of HRF. Withaferin A and Triptolide inhibit NF-κB activation, indirectly influencing HRF expression. Withaferin A suppresses NF-κB activation, altering HRF expression. Triptolide hampers the nuclear translocation of NF-κB, leading to modulation of HRF expression. In summary, HRF inhibitors provide a versatile toolkit for precise modulation of HRF expression through the targeted inhibition of the NF-κB signaling pathway.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $130.00 | 12 | |
NF-κB inhibitor impacting HRF indirectly by inhibiting NF-κB signaling, a pathway in which HRF is involved. TPCA-1 disrupts the activation of NF-κB, which can regulate the expression of HRF. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
IKK inhibitor influencing HRF indirectly by suppressing NF-κB activation. BAY 11-7082 impedes the activity of IKK, a kinase upstream of NF-κB, resulting in decreased NF-κB-mediated transcriptional regulation of HRF. | ||||||
Parthenolide | 20554-84-1 | sc-3523 sc-3523A | 50 mg 250 mg | $79.00 $300.00 | 32 | |
NF-κB inhibitor impacting HRF indirectly by inhibiting the activation of NF-κB, a transcription factor involved in the regulation of HRF. Parthenolide suppresses the nuclear translocation of NF-κB, thereby modulating HRF expression. | ||||||
NFκB Activation Inhibitor II, JSH-23 | 749886-87-1 | sc-222061 sc-222061C sc-222061A sc-222061B | 5 mg 10 mg 50 mg 100 mg | $210.00 $252.00 $1740.00 $1964.00 | 34 | |
Inhibitor of NF-κB nuclear translocation indirectly affecting HRF expression. JSH-23 prevents the nuclear import of NF-κB, a transcription factor that regulates HRF expression. | ||||||
BAY 11-7085 | 196309-76-9 | sc-202490 sc-202490A | 10 mg 50 mg | $122.00 $516.00 | 55 | |
NF-κB inhibitor that influences HRF indirectly by inhibiting the activation of NF-κB, a transcription factor involved in the regulation of HRF. Bay 11-7085 hinders the nuclear translocation of NF-κB, leading to modulation of HRF expression. | ||||||
Celastrol, Celastrus scandens | 34157-83-0 | sc-202534 | 10 mg | $155.00 | 6 | |
Inhibitor of NF-κB activation indirectly affecting HRF expression. Celastrol impedes the nuclear translocation of NF-κB, a transcription factor regulating HRF, and thus modulates HRF expression. | ||||||
IMD 0354 | 978-62-1 | sc-203084 | 5 mg | $199.00 | 3 | |
IKKβ inhibitor impacting HRF indirectly through inhibition of NF-κB signaling. IMD-0354 hampers the activity of IKKβ, a kinase upstream of NF-κB, leading to decreased NF-κB-mediated transcriptional regulation of HRF. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor affecting HRF indirectly by preventing NF-κB activation. Bortezomib inhibits the degradation of IκB, an inhibitor of NF-κB, leading to the suppression of NF-κB-mediated transcriptional regulation of HRF. | ||||||
Caffeic acid phenethyl ester | 104594-70-9 | sc-200800 sc-200800A sc-200800B | 20 mg 100 mg 1 g | $70.00 $290.00 $600.00 | 19 | |
NF-κB inhibitor impacting HRF indirectly by inhibiting the activation of NF-κB, a transcription factor involved in the regulation of HRF. CAPE suppresses the nuclear translocation of NF-κB, modulating HRF expression. | ||||||
Wedelolactone | 524-12-9 | sc-200648 sc-200648A | 1 mg 5 mg | $108.00 $330.00 | 8 | |
IKK inhibitor affecting HRF indirectly through modulation of NF-κB signaling. Wedelolactone inhibits IKK, a kinase upstream of NF-κB, leading to decreased NF-κB-mediated transcriptional regulation of HRF. | ||||||